glp-1 agonists and sglt2 inhibitors combination GLP1 Receptor vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Metabolic and cardiovascular benefits with

For semaglutide , a phase 2 trial published in the New England Journal of Medicine (2021) examined daily semaglutide 0.4 mg in NASH patients and found that 59% achieved NASH resolution compared to 17% with placebo

By balancing the potential benefits and risks of treatment using evidence-based strategies, HCPs are well placed to help optimise the use of GLP-1 RAs in the management of obesity and overweight

Caloric Expenditure : Studies indicate that GLP-1 may increase energy expenditure by promoting the utilization of calories, thereby assisting in weight loss efforts

And sometimes, its caused by a GLP-1. According to Dr

These effects collectively mitigate oxidative damage and support neuronal survival, potentially having a beneficial role in PD pathogenesis [78]

Microdoses maintain metabolic benefits while minimizing nausea and GI upset that cause many patients to quit therapy